{"id":"W3211966340","doi":"10.1182/blood-2021-145694","title":"Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Lenalidomide; Follicular lymphoma; Internal medicine; Refractory (planetary science); Population; Cytokine release syndrome; Oncology; Gastroenterology; Lymphoma; Cancer; Multiple myeloma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001123854,0.0006352639,0.001260229,0.0002409563,0.0003118954,0.0008361771,0.000529119,0.0005477126,0.001573287],"category_scores_gemma":[0.000704111,0.0003024182,0.0007490295,0.0003146221,0.000403854,0.0004513046,0.0002172047,0.001519995,0.0005285988],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006804185,"about_ca_system_score_gemma":0.0006755807,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008883279,"about_ca_topic_score_gemma":0.001937005,"domain_scores_codex":[0.999665,0.0001501428,0.00002754694,0.00004427909,0.00005179283,0.00006115528],"domain_scores_gemma":[0.9996367,0.00007908205,0.00006873651,0.00003901565,0.00002829827,0.0001481798],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3349621,0.05042932,0.03991757,0.001069669,0.002869739,0.000960458,0.0007219376,0.002829115,0.1853029,0.0001864966,0.005636371,0.3751144],"study_design_scores_gemma":[0.1906622,0.646463,0.12177,0.0001282815,0.002317426,0.002231302,0.0002408709,0.003254398,0.02177916,0.0002369999,0.01085446,0.00006191483],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953075,0.002726657,0.0002106704,0.0001554287,0.00001780883,0.0002866453,0.0002629628,0.00004076502,0.0009915683],"genre_scores_gemma":[0.9964476,0.001274165,0.0004410453,0.0002374496,0.00006428218,0.0002000444,0.0006871121,0.00001401837,0.0006343229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001573287,"threshold_uncertainty_score":0.005943596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01316604419978641,"score_gpt":0.2454539305690137,"score_spread":0.2322878863692273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}